🔗 Permalink

Inventor profile of:

RAPHAËL DARTEIL

City:

LYON

Country:

France

Published Applications:

Last publication date:

2025-01-16

Recent patent applications by DARTEIL RAPHAËL

RAPHAËL DARTEIL from LYON, FR has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-01-16

US20250019370A1

Chemistry; metallurgy

L-LYSINE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF

#2 | 2025-01-16

US20250019358A1

Chemistry; metallurgy

L-LYSINE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF

#3 | 2024-12-12

US20240410010A1

Chemistry; metallurgy

NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS

#4 | 2024-07-04

US20240216364A1

Human necessities

STRONG POTENTIATION OF TLR3 AGONISTS EFFECTS USING FXR AGONISTS AS A COMBINED TREATMENT

#5 | 2024-05-16

US20240156778A1

Human necessities

THIOPHENE DERIVATIVES FOR USE IN TREATING PORTAL INFLAMMATION AND FIBROSIS

#6 | 2024-03-28

US20240100125A1

Human necessities

SYNERGISTIC EFFECT OF A FXR AGONIST AND IFN FOR THE TREATMENT OF HBV INFECTION

#7 | 2023-10-12

US20230321033A1

Human necessities

THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS

#8 | 2023-06-01

US20230165853A1

Human necessities

METHOD FOR TREATING CHRONIC KIDNEY DISEASES

#9 | 2023-03-02

US20230060715A1

Human necessities

USE OF FXR AGONISTS FOR TREATING AN INFECTION BY HEPATITIS D VIRUS

#10 | 2022-10-06

US20220313690A1

Human necessities

SYNERGISTIC EFFECT OF EYP001 AND IFN FOR THE TREATMENT OF HBV INFECTION

#11 | 2022-08-11

US20220249469A1

Human necessities

IMPROVED TREATMENT USING EYP001

#12 | 2022-08-04

US20220241376A1

Human necessities

METHOD FOR DECREASING ADVERSE-EFFECTS OF INTERFERON

InventorID:

5478593 ⎘